Roche reports a strong start in 2019 and raises the outlook for the full-year
(WorldNews Switzerland)

Basel, 17 April 2019 Roche reports a strong start in 2019 and raises the outlook for the full-year Group sales increase 8%1 at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor Important approvals in the first quarter. In the US: Tecentriq combination therapy for extensive-stage small cell lung cancer; Tecentriq combination therapy for triple-negative breast cancer and companion diagnostic test; Herceptin Hylecta for subcutaneous injection for breast cancer; in the EU: Hemlibra for people with severe haemophilia A...